Among the numerous CAIX-targeted imaging probes reported, radiolabeled girentuximab-based tracers are the most clinically investigated agents, and it was recently demonstrated that [89Zr]Zr-labeled girentuximab could successfully distinguish ccRCC from non-ccRCC lesions. The gene discussed is CA9; the disease is nonpapillary renal cell carcinoma.